Analysts who follow BioXcel Therapeutics Inc (BTAI) on average expect it to add 145.61% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns BTAI an Analyst Ranking of 26, which means it ranks higher than 26 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating BTAI a Buy today. Find out what this means to you and get the rest of the rankings on BTAI!
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With BioXcel Therapeutics Inc Stock Today?
BioXcel Therapeutics Inc (BTAI) stock has gained 0.53% while the S&P 500 is unmoved 0% as of 2:28 PM on Friday, Mar 22. BTAI has gained $0.02 from the previous closing price of $2.83 on volume of 201,345 shares. Over the past year the S&P 500 is up 32.74% while BTAI is lower by -84.38%. BTAI lost -$6.15 per share the over the last 12 months.
Click Here to get the full Stock Report for BioXcel Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
